Recent medical device IPOs have fallen in value an average of 14%; but even at their current low valuations, returns to private investors remain healthy. For this reason, it is likely that new IPOs will be priced far closer to the valuations of the last private rounds than they were in the IPOs of 1996-97. This Start-Up analysis also reveals that, contrary to conventional industry wisdom, companies who went public with earlier stage products have generated higher returns to both private and public investors.
by Stephen Levin and Roger Longman
What a difference a year makes—in 1996, two-thirds of the attendees at the annual fall Phoenix conference for medical device...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.
CEO Alexandre Chau told Medtech Insight that the Middle East and Africa presented the ideal mix of market potential, physician training opportunities, and regulatory readiness when the company was considering expansion markets beyond Europe and the US.
Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.
The Milner Institute, the on-campus hub for start-up acceleration at Cambridge University, hosted its annual Pitch Day on July 1. Start-ups Panakeia, PathwayBio and Sentinal4D presented diagnostic technologies.
Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.
The Milner Institute, the on-campus hub for start-up acceleration at Cambridge University, hosted its annual Pitch Day on July 1. Start-ups Panakeia, PathwayBio and Sentinal4D presented diagnostic technologies.
To succeed in medtech, investors must focus on patient outcomes. Gilde Healthcare says involving patients boosts product effectiveness, access and market success — making it a smart strategy in today’s strained healthcare systems.
